Compounding that statistic, prior studies indicate some trans people at high risk for HIV transmission are hesitant to take ...

The Trump administration's funding cuts to PEPFAR and USAID disrupted global HIV treatment and prevention, threatening progress made over decades. Lenacapavir's FDA approval as a long-acting ...

Gilead Sciences, Inc. GILD announced that the investigational single-tablet regimen of bictegravir and lenacapavir for the ...

With a second late-stage trial win for its investigational HIV combo in the books, Gilead Sciences is moving full steam ahead ...

Gilead Sciences said on Monday its experimental HIV treatment was found to be statistically non-inferior to its top-selling ...

Gilead said its two-drug bictegravir-lenacapavir tablet was non-inferior to Biktarvy in the Phase 3 ARTISTRY-2 HIV trial.

Gilead Sciences said its in-development HIV treatment met the primary endpoint of a recent late-stage clinical trial. The biopharmaceutical company said Monday that the treatment, a once-daily single ...

Gilead Sciences said on Monday its experimental HIV treatment met the main goal in a late-stage trial. The treatment regimen ...

The Herald (Top Stories) Rumbidzayi Zinyuke recently in ACCRA, Ghana AT LEAST 46 500 people will be put on the long-acting HIV prevention drug Lenacapavir early next year, as Zimbabwe begins its first ...

Source: 46 000 high – risk individuals to receive long acting HIV prevention drug | The Herald (Top Stories) Rumbidzayi Zinyuke recently in Accra, Ghana A TOTAL of 46 500 people will be put on the ...

This study investigates how the HIV inhibitor lenacapavir influences capsid mechanics and interactions with the nuclear pore complex. It provides important insights into how drug-induced ...

The U.S. and Eswatini have entered a five-year health cooperation agreement involving a $242 million understanding to enhance ...